Sale

Neurodegenerative Diseases Drugs Market

Global Neurodegenerative Diseases Drugs Market Share, Size, Trends, Growth, Analysis, Forecast: By Drug Class: Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others; By Disease Indication: Multiple Sclerosis, Others; By Route of Administration; By End-User; Regional Analysis; Competitive Landscape; 2024-2032

Global Neurodegenerative Diseases Drugs Market Outlook

The global neurodegenerative diseases drugs market size attained a value of over USD 44.69 billion in 2023. The market is expected to grow at a CAGR of 7.1% between 2024 and 2032, driven by increasing prevalence of various neurodegenerative diseases.

 

neurodegenerative diseases drugs market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Trends in the Market

Neurodegenerative diseases drugs are the medications aimed at treating neurodegenerative diseases such as Alzheimer’s, multiple sclerosis, and spinal muscular atrophy, among others. These types of drugs can be taken orally, intravenously, or through the skin. Neurodegenerative diseases refer to those diseases and conditions that are caused by a loss in performance or structure of neurons, as a result of the neurodegeneration process.

 

  • The global neurodegenerative diseases drugs market growth is being propelled by the rising prevalence of cases of neurodegenerative diseases such as Alzheimer’s, Parkinson’s disease, and multiple sclerosis. The increasing geriatric population is further escalating the incidences of these diseases, as likelihood of developing these diseases surges with age.
  • As there is currently no cure for neurodegenerative diseases and based on the disease, slowing the progression can also be difficult, the importance of neurodegenerative diseases drugs in combating symptoms is vital. Early and regular intake of neurodegenerative diseases drugs can help control the disease.
  • Increasing innovations and research and development expenditure in the pharmaceutical sector across the emerging economies are further bolstering the innovations of neurodegenerative diseases drugs. In addition, the repurposing of old neurodegenerative diseases drugs is another crucial market propelling factor.
  • The growing approvals of newly developed drugs by regulatory authorities, such as the United States’ FDA are key trends in the neurodegenerative diseases drugs market. Regulatory approval helps support the wider access of these drugs, enabling more patients to use them.

 

Market Analysis

 

neurodegenerative diseases drugs market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on drug class, the market is segmented into immunomodulator, interferons, decarboxylase inhibitors, and dopamine agonists, among others. On the basis of disease indication, the market is classified into multiple sclerosis, Parkinson’s disease, Alzheimer's disease, and spinal muscular atrophy (SMA), among others. By route of administration, the market is divided into oral, injection, and transdermal. Based on end-user, the market is categorised into hospital pharmacy, retail pharmacy, and online. The regional markets can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. 

 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global neurodegenerative diseases drugs market, covering their competitive landscape and latest developments like mergers, acquisitions, investments and expansion plans. 

 

  • Pfizer, Inc.
  • Merck KGaA
  • Novartis AG
  • Acadia Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • Others

 

Market Share by Disease Indication

The Alzheimer's disease segment, based on disease indication, holds a significant share in the neurodegenerative diseases drugs market, owing to the high prevalence of this disease among the elderly. The increasing geriatric population is leading to an escalation of the cases of Alzheimer’s disease which is in turn boosting the sale of drugs intended towards treating cognitive manifestations related to this disease. Meanwhile, cases of Parkinson’s disease are also escalating worldwide, supported by growing awareness and faster diagnoses. Over the forecast period, the increase in awareness about these diseases, along with early diagnostic tools and protocols are expected to fuel the neurodegenerative diseases drugs market growth.  

 

Market Share by Region

The North America region accounts for a significant share in the market for neurodegenerative diseases drugs due to the increasing cases of Alzheimer’s disease across the United States. In addition, the high healthcare expenditure across the country is enhancing the accessibility of neurodegenerative diseases drugs across hospitals pharmacies and various other healthcare units. The strong presence of drug manufacturers across this region is another crucial neurodegenerative diseases drugs market driving factor. 

 

In the forecast period, the Asia Pacific is expected to witness a steady growth in the market for neurodegenerative diseases drugs. The demand for neurodegenerative diseases drugs in this region is expected to be driven by the rising geriatric population across the emerging economies such as India and China which are anticipated to increase the cases of neurodegenerative diseases.  

 

neurodegenerative diseases drugs market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

Pfizer, Inc. is one of the largest pharmaceutical manufacturers across the world. This company was founded in the year 1849 and is currently headquartered in New York, United States. Pfizer, Inc. produces medications, drugs, and vaccines, aimed towards battling chronic diseases. It is known for the development of remarkable breakthroughs in the field of pharmaceuticals.

 

Merck KGaA, founded in the year 1668 and currently headquartered in Darmstadt, Germany, is a leading science and technology company, and one of the oldest pharmaceutical companies around the world. It delivers progressive treatment solutions, personalised treatments,  and healthcare products for oncology, endocrinology, fertility, neurology, immunology, and general medicine. Apart from healthcare, Merck also specialises in electronics and life sciences. 

 

Novartis AG is a pharmaceutical firm based in Basel, Switzerland. It was founded in the year 1997 and currently innovates and sells medicines and drugs to cure various chronic diseases. Novartis AG has been structured into two companies namely, Innovative Medicines and Sandoz. The company is also a prominent player in the field of science and technology. 

 

Other market players include Acadia Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and F. Hoffmann-La Roche Ltd, among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Disease Indication
  • Route of Administration
  • End-User
  • Region
Breakup by Drug Class
  • Immunomodulator
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Others
Breakup by Disease Indication
  • Multiple Sclerosis
  • Parkinson’s Disease
  • Alzheimer's Disease
  • Spinal Muscular Atrophy (SMA)
  • Others
Breakup by Route of Administration
  • Oral
  • Injection
  • Transdermal
Breakup by End-User
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Pfizer, Inc.
  • Merck KGaA
  • Novartis AG
  • Acadia Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • Others

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface 
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions   
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments  
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Region
7    Industry Opportunities and Challenges  
8    Global Neurodegenerative Diseases Drugs Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Neurodegenerative Diseases Drugs Historical Market (2018-2023) 
    8.3    Global Neurodegenerative Diseases Drugs Market Forecast (2024-2032)
    8.4    Global Neurodegenerative Diseases Drugs Market by Drug Class
        8.4.1    Immunomodulator 
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2018-2023)
            8.4.1.3    Forecast Trend (2024-2032)
        8.4.2    Interferons 
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2018-2023)
            8.4.2.3    Forecast Trend (2024-2032)
        8.4.3    Decarboxylase Inhibitors 
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2018-2023)
            8.4.3.3    Forecast Trend (2024-2032)
        8.4.4    Dopamine Agonists 
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2018-2023)
            8.4.4.3    Forecast Trend (2024-2032)
        8.4.5    Others
    8.5    Global Neurodegenerative Diseases Drugs Market by Disease Indication
        8.5.1    Multiple Sclerosis 
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2018-2023)
            8.5.1.3    Forecast Trend (2024-2032)
        8.5.2    Parkinson’s Disease 
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2018-2023)
            8.5.2.3    Forecast Trend (2024-2032)
        8.5.3    Alzheimer's Disease 
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2018-2023)
            8.5.3.3    Forecast Trend (2024-2032)
        8.5.4    Spinal Muscular Atrophy (SMA) 
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2018-2023)
            8.5.4.3    Forecast Trend (2024-2032)
        8.5.5    Others
    8.6    Global Neurodegenerative Diseases Drugs Market by Route of Administration
        8.6.1    Oral 
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2018-2023)
            8.6.1.3    Forecast Trend (2024-2032)
        8.6.2    Injection 
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2018-2023)
            8.6.2.3    Forecast Trend (2024-2032)
        8.6.3    Transdermal
            8.6.3.1    Market Share
            8.6.3.2    Historical Trend (2018-2023)
            8.6.3.3    Forecast Trend (2024-2032)
    8.7    Global Neurodegenerative Diseases Drugs Market by End-User
        8.7.1    Hospital Pharmacy 
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2018-2023)
            8.7.1.3    Forecast Trend (2024-2032)
        8.7.2    Retail Pharmacy 
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2018-2023)
            8.7.2.3    Forecast Trend (2024-2032)
        8.7.3    Online    
            8.7.3.1    Market Share
            8.7.3.2    Historical Trend (2018-2023)
            8.7.3.3    Forecast Trend (2024-2032)
    8.8    Global Neurodegenerative Diseases Drugs Market by Region
        8.8.1    Market Share
            8.8.1.1    North America
            8.8.1.2    Europe
            8.8.1.3    Asia Pacific
            8.8.1.4    Latin America
            8.8.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2018-2023)
        9.1.2    Forecast Trend (2024-2032)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2018-2023)
        9.2.2    Forecast Trend (2024-2032)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2018-2023)
        9.3.2    Forecast Trend (2024-2032)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2018-2023)
        9.4.2    Forecast Trend (2024-2032)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2018-2023)
        9.5.2    Forecast Trend (2024-2032)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Competitive Landscape
    11.1    Market Structure
    11.2    Company Profiles
        11.2.1    Pfizer, Inc. 
            11.2.1.1    Company Overview
            11.2.1.2    Product Portfolio
            11.2.1.3    Demographic Reach and Achievements
            11.2.1.4    Certifications
        11.2.2    Merck KGaA
            11.2.2.1    Company Overview
            11.2.2.2    Product Portfolio
            11.2.2.3    Demographic Reach and Achievements
            11.2.2.4    Certifications
        11.2.3    Novartis AG 
            11.2.3.1    Company Overview
            11.2.3.2    Product Portfolio
            11.2.3.3    Demographic Reach and Achievements
            11.2.3.4    Certifications
        11.2.4    Acadia Pharmaceuticals Inc.
            11.2.4.1    Company Overview
            11.2.4.2    Product Portfolio
            11.2.4.3    Demographic Reach and Achievements
            11.2.4.4    Certifications
        11.2.5    Teva Pharmaceutical Industries Ltd.
            11.2.5.1    Company Overview
            11.2.5.2    Product Portfolio
            11.2.5.3    Demographic Reach and Achievements
            11.2.5.4    Certifications
        11.2.6    F. Hoffmann-La Roche Ltd
            11.2.6.1    Company Overview
            11.2.6.2    Product Portfolio
            11.2.6.3    Demographic Reach and Achievements
            11.2.6.4    Certifications
        11.2.7    Others
12    Industry Events and Developments

 

List of Key Figures and Tables

1.    Global Neurodegenerative Diseases Drugs Market: Key Industry Highlights, 2018 and 2032
2.    Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Drug Class (USD Million), 2018-2023
3.    Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Drug Class (USD Million), 2024-2032
4.    Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Disease Indication (USD Million), 2018-2023
5.    Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Disease Indication (USD Million), 2024-2032
6.    Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Route of Administration (USD Million), 2018-2023
7.    Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Route of Administration (USD Million), 2024-2032
8.    Global Neurodegenerative Diseases Drugs Historical Market: Breakup by End-User (USD Million), 2018-2023
9.    Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by End-User (USD Million), 2024-2032
10.    Global Neurodegenerative Diseases Drugs Historical Market: Breakup by Region (USD Million), 2018-2023
11.    Global Neurodegenerative Diseases Drugs Market Forecast: Breakup by Region (USD Million), 2024-2032
12.    North America Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2023
13.    North America Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Europe Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2023
15.    Europe Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Asia Pacific Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2023
17.    Asia Pacific Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2024-2032
18.    Latin America Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2023
19.    Latin America Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2024-2032
20.    Middle East and Africa Neurodegenerative Diseases Drugs Historical Market: Breakup by Country (USD Million), 2018-2023
21.    Middle East and Africa Neurodegenerative Diseases Drugs Market Forecast: Breakup by Country (USD Million), 2024-2032
22.    Global Neurodegenerative Diseases Drugs Market Structure.

Key Questions Answered in the Report

The global market size for neurodegenerative diseases drugs reached a value of more than USD 44.69 billion in 2023.

The market is estimated to grow at a CAGR of 7.1% in the forecast period of between 2024 and 2032.

The rising prevalence of neurodegenerative diseases, increasing geriatric population, growing expansion of the healthcare sector across the emerging economies are the major drivers of the neurodegenerative diseases drugs market.

The key trends in the market include the growing regulatory approvals by bodies such as the United States’ FDA of newly developed drugs, progressive product innovations, and rising awareness among the people.

Immunomodulator, interferons, decarboxylase inhibitors, and dopamine agonists, among others, are the different drug classes in the market.

Multiple sclerosis, Parkinson’s disease, Alzheimer's disease, and spinal muscular atrophy (SMA), among others, is the segmentation of the market based on disease indication.

Oral, injection, and transdermal are the major routes of administrations based on which the market has been divided.

North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa, are the major regional markets.

Currently, there is no cure for neurodegenerative diseases, however, the drugs and supportive treatments are available to help slow down the disease progression and combat symptoms.

Pfizer, Inc., Merck KGaA, Novartis AG, Acadia Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and F. Hoffmann-La Roche Ltd, among others, are the key market players, according to the report.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER